Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
Very true nicely, as mentioned below we are in week 6 since first dose so news is due. In regards to raising- from my experience here even if they raised at a lows the takeup woudl be good.
The previous ones have all been oversubscribed and we were no where near clinic at those times. So now we are clinic stage and in-human and they go to the next cohort which means the safety profile is validated further then even a raise then would be oversubscribed in my opinion. That said in the RNS they specifically said a raise would only happen at ph1b and then that would be to take 1801 into a respiratory trial alongside Psoriasis.
So all in all I'm chilled whilst the price goes yoyo as usual.
Nicely, maybe so- but then as with most other companies who go through trials I would expect an RNS for each cohort increase.
I believe we are end the end of one now or thereabouts so an RNS for a dose increase to the next cohort should be in good order but lets see how things pan out.
It is clearly an engineered drop anyone who cannot see this is blind.
In Oct past year prior the Gsk returning Chk1 we were around £2 and still a pre-clinical company with a lot of uncertainty around 1801.
We have now transformed into a clinical stage company, first dosed 6th June safety committee has not stopped the trial and we are sitting around £1- go figure.
We have also got 2 new patents one specifically targeting China for 1801 with Australia being a direct route to it and have been told 1802 has had acute tox studies done and will be going straight into cancer patients not healthy subjects in ph1 and have received a US patent for auto-immune for it aswell.
The price to position disconnect is glaringly visible- so it is position building or order filling as we have a insofar non-toxic capsule in clinic with no mtd treating Psoriasis and will also look to respirtory illnesses in ph1b. The trial is being controlled by the safety committee not Sareum and any bad news would have been immediately announced.
Makes you wonder but then who is the market leader in Psoriasis- Humira only intravenous (injection) with loads of side affets but still pulling in $1bn per month- now imagine only having to take a capsule once a day with no side effects- wouldn't you want a punt on that and it is what is driving potential position building and remember Dr Reader has already said ph1b efficacy will be gamechanging.
Hot, I believe Sar intend to run a respiratory trial incoginito with Psoriasis as per the half yearly report-
The Phase 1a part of the trial is expected to provide safety and dosing information applicable for any future trials in patients with other autoimmune diseases, and potentially in patients with the acute respiratory symptoms of viral infections should the Company decide to progress such trials.
1801 like 1802 is multi-applicable- the exciting thing is that 1802 has had acute tox studies already done and will be going straight into patients not healthy subjects as per the investor meet pres.
In my opinion it's multi-applicability it outstanding hence why they have also applied for and receiced a US patent confirmed last month for auto-immune to go along with their cancer patents.
As for no doubt of me being a ramper- now if I was frequently saying we're going to the moon, boom etc. then maybe you would have a shout.
But your barking up the wrong tree fella look at my posting history- I have said a many time that we could fail, let's see how it pans out, no guarantees of success or invitro safety being matched in human.
It's enthusiam not ramping, maybe over enthusiatic- but then I have seen my 30k investment go as low as 9k as high as 300k and everything inbetween even after selling half to meet cost associated with my fathers death I am in healthy profit and Sareum are a totally more validated company then when I invested over 10yrs ago- so anyone who has been through a similar path as me would be a tad bit enthusiatic now we are finally in clinic first dosed on 6 June and the safety committee have not pulled the plug.
Says it all really, we are now a clinical stage company taking the Tyk2 Jak1 route as Thoth predicted all those years ago.
bluenose53
Posted in: SAR
Posts: 856
Price: 3.70
No Opinion
RE: Thoth…5 Feb 2022 22:26
Another tall tale from the book of Thoth’s Fables no doubt!
Yeah, thats it I'm not getting paid enough. Maybe you should look at your own profile and posts to see transparency- being deliberetly obtuse always gets you caught you know, maybe your paymaster forgot to tell you that.
And it seems you've become delusional as well as I don't post on other boards. For your info. I am also invested in PHP and Avct and you can see clearly the difference in poster type across the 2 like here. Luckly for me I am in a very good position and actually invested not like you.
Maybe look at my last post about twatfuddry then look at your posting history and draw similarities. 🙃
Toodle pip.
You're right bluenose- it's a death trap. Run for dear life chap- I'm concerned now as well.
So now that you've sold and are taking your chances with you imaginery hard earned elsewhere I take it you won't be posting again yeah.
Ta cheers bye bye
And good research to back up the FUD though 7 out 10
That is hilarious- it's a safety trial in healthy volunteers like 1000000/1 chance of that happening I believe unless they mixed 1801 with bleach and vimto and take this and lets see how you bounce.
ADVFM- 🤦♂️
Aber, I agree. I was just spelling out where we are at. I half expect mtd to be found end of year at least and at a significant dose as we are very efficacious as seen pre-clinically- although invitro is not always a guide to human outcome so let's see how things pan out.
In the meantime it would be rude not to top up at these prices- seems like someone is building a position we are only afterall trying to pi.. on Abbvie's Humira parade with a potentially non toxic once daily capsule against their injection which pulls in $1bn per month.
Alan as per my last post below. It's taking forever because it's a in-human trial ph1a safety- it is out of Sareums control.
The safety committee are controlling the trial and to say we are first dosed on 6th June and the trial has not been stopped goes to show we are looking good as the capsules are insofar safe so likely to have a dosage increase which mean next cohort or they have found mtd in which case we go to ph1b efficacy i.e. into hospital and patients.
Total FUD-
Don't worry Surfie I was holding when we were less than half a penny old money which would likely equate to 50p new money and we were not in clinic and only had 1 tyk2.
We are now a clinical stage company and have:
- Chk1 ph2/3 ready,
- 1801 in clinical trials, capsule form targeting Psoriasis which effects more than 60 million adults worldwide, with a market size for potential treatments estimated to be worth more than US$30 billion.
-1802 almost ph1 ready twice worldwide patented in cancer and have only announced last month that a US patent to cover auto-immune illnesses as well for which it was successfully trialled by the US Army in Lupus.
As mentioned the price will yoyo until ph1b efficacy we are in ph1a safety and insofar the safety committee has not stopped the trial.
So I believe we are in a much more advanced position than when I was holding sub 1p or sub £1 to 50p post consolidation- so nothing to worry about at all.
June 2023- 1801
The China National Intellectual Property Administration (CNIPA) has officially issued patent number CN113056456B, safeguarding SDC-1801 and medical applications of it in treating inflammatory or immune disorders.
1802-
The United States Patent and Trademark Office (USPTO) has formally granted patent number US 11,673,870 B2 specifically covering the treatment of autoimmune disorders with SDC-1802 and several analogues. While Sareum has previously secured international patents providing comprehensive protection for the compound SDC-1802, this patent extends its scope in the US beyond immuno-oncology.
Tyk2 Japan and China patent 2017-
This patent* describes compounds that inhibit JAK kinase enzyme function, in particular TYK2 kinase. It also describes the use of these compounds in the treatment of disease mediated by these kinase enzymes, including autoimmune diseases such as multiple sclerosis, psoriasis and inflammatory bowel disease.
The granting of the Japanese patent and the imminent granting of the Chinese patent mean that Sareum will have approved patent protection in Japan and China for its TYK2 inhibitor programme. Similar patent protection in Europe was announced on 10 November 2014 and the Company expects that similar patents will be granted in other major markets, including the USA, in due course.
* Japanese Patent no. 6239118, Chinese Patent Application no. 201380080517X
1802 (the biggy in most investors eyes) again a 100% owned Tyk2/Jak1 cancer compound likely also once daily capsule as per AGM using 1801 study as testing pad. Twice world-wide patent protected with the last 2 patents for the first time in our history naming target indications-
Euro patent grant-
The patent will come into effect on 4 May 2022.
The patent (EPO Patent no. EP3528806) will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat T-cell acute lymphoblastic leukaemia (T-ALL - a cancer of a particular type of white blood cell called a T lymphocyte) and other cancers that are dependent on TYK2 kinase for survival. This programme is in preclinical development".
- And the US patent grant in 2021-
The patent (US 11,154,539) will grant on 26 October 2021 and will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase.
Many happy returns chaps- The appearance of the dirt means we are closer to positive has observed a many a time before.
Heavens Potnak, surely you cannot compare our BOD to Vals. I've been invested in that mess for as long as here I think well 7yrs+ and I'm 3k down.
Fortunately for me like you, Laz and I am sure many others I am also on a free ride of 38k shares well in profit having sold half just before ot around consolidation to pay for my things when my father passed away.
As you quite rightly say and what I pointed out to that clown funny last night is if it fails we lose money as well but we cannot control human trials. The positive for me is that we are now finally in clinic and insofar the safety committee has not pulled the plug so looks good and if something did go pear shaped it's a precursor to 1802 which will hopefully learn from whatever did go upsy with 1801 but still would be a pain to see the price tank nonetheless.
Anyhoo- chin up fella, tyk2 jak1 as Sad and many others will tell you is the future as our late Thoth predicted all those years ago- just a matter of getting to ph1b efficacy as preclinically we have aced safety so no reason for it not to in ph1a.
Funny, your a tool- maybe you should look at the posting history of people before you judge.
I don't mind negative views infact I welcome them as long as they are backed with some research, workings out or evidence.
I am uber enthusiatic but not a ramper as some c..wombles have lablled me- I've been invested 11yrs+ when we were as low as 0.0025p seeing my 30k investment valued at 9.5k hence why I'm calm about it all. What gets me is the derampers and fuders posting without anything to back it up- then having sissy when being called out.
Seawolf, you could be right get to ph1b with little to no tox, high mtd or a therapauetically effective dose and be treating Psoriasis with a once daily capsule and we could be gone.
The money is definitely out there-
https://www.goldmansachs.com/intelligence/pages/pharmaceutical-companies-have-700-billion-for-acquisition.html
Relax chap- the whole thing is out of Sareums hands-The safety committee are in charge of the trial and it's a in-human trial which cannot be rushed for the benefit of investors, traders etc.
As Laz points out bad news would have long been out by now and the safety committee are indepedant and have no financial gain from this or any other trial for that matter- to think otherwise would be wholly unethical.
I am sure we will hear the relevant news whether that be next cohort as no mtd found or mtd found end of ph1a and move to ph1b efficacy.
It is unusual for an RNS not to drop regarding cohort increase so I do half expect one but stranger things have happened. Nonetheless, I am chipper with the fact the safety committe has not halted the trial as yet so things must be going well.